TIGIT (RM) [BLR047F]

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain (TIGIT) is a transmembrane glycoprotein receptor expressed in regulatory and memory T cells, natural killer (NK), and activated T cells (1). As a member of the immunoglobulin superfamily, TIGIT has coinhibitory effects on T-cell dependent immune responses, playing an important role in transplantation tolerance and tumor immune surveillance (2,3). Several studies indicate that TIGIT exhibits synergistic function with the PD-1/PD-L1 pathway in the inhibition of Tcell proliferation. Co-blockade of TIGIT in conjunction with other checkpoint receptors, such as PD-1, has been investigated as a promising immunotherapy in multiple ongoing clinical trials (4).

Specifications

1. Kurtulus S, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–4062.
2. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923– 937.
3. Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723–732.
4. Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. 2019 Nov 6.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.